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Graphical abstract 
 
 
ABSTRACT 
 
Neuronal injury plays a major role in diabetic retinopathy (DR). Our hypothesis was that the balance 
between neuronal death and survival may depend on a similar equilibrium between apoptosis and 
autophagy and that a neuroprotectant may act by influencing this equilibrium. Ex vivo mouse retinal 
explants were treated with high glucose (HG) for 10 days and the somatostatin analog octreotide 
(OCT) was used as a neuroprotectant. Chloroquine (CQ) was used as an autophagy inhibitor. 
Apoptotic and autophagic markers were evaluated using western blot and immunohistochemistry. 
HG-treated explants displayed a significant increase of apoptosis paralleled by a significant 
decrease of the autophagic flux, which was likely to be due to increased activity of the autophagy 
regulator mTOR (mammalian target of rapamycin). Treatment with OCT rescued HG-treated retinal 
explants from apoptosis and determined an increase of autophagic activity with concomitant mTOR 
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inhibition. Blocking the autophagic flux with CQ completely abolished the anti-apoptotic effect of 
OCT. Immunohistochemical observations showed that OCT-induced autophagy is localized to 
populations of bipolar and amacrine cells and to ganglion cells. These observations revealed the 
antithetic role of apoptosis and autophagy, highlighting their equilibrium from which neuronal 
survival is likely to depend. These data suggest the crucial role covered by autophagy, which could 
be considered as a molecular target for DR neuroprotective treatment strategies. 
 
Keywords: Autophagic flux, Apoptosis, Somatostatin, Bipolar cells, Amacrine cells, Ganglion cells. 
 
 
1. Introduction 
 
Diabetic retinopathy (DR) is a leading cause of blindness in the world. Because of its typical 
vascular dysfunctions and aberrant angiogenesis, this disease has long been considered exclusively 
as a microvascular disorder of the retina. However, that neuronal injury plays a major role in DR is 
gaining increasing recognition [1-4]. 
Apoptotic pathways are known to participate in the death of retinal cells under different 
noxious stimuli, including diabetic stress, but autophagy, a catabolic pathway that promotes the 
degradation and recycling of cellular components, has also been recognized to be involved in the 
fate of stressed retinal neurons [5, 6]. A variety of studies has been concerned with the possible 
roles of autophagy in DR [7-11]. Although the modulation of autophagic signaling, with consequent 
autophagy dysregulation, is likely to be involved in the pathogenesis of DR [11-13], whether high 
glucose (HG) levels determine an increase of the autophagic flux or, instead, inhibit autophagy, has 
not been established unambiguously. Indeed, in retinal pigment epithelial cells, HG has been 
observed to cause a marked increase in autophagy and autophagosome formation [14, 15], while in 
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Müller cells HG has been observed to disrupt autophagy and induce cargo accumulation due to 
lysosomal dysfunction [13].  
Another interesting point is whether we should expect pro-survival or pro-death effects of 
autophagy in DR [8, 11, 16]. Apoptosis and necrosis seem to establish a strict relationship with 
autophagy, which may function as a cell death route or may initiate a cell protective response [17]. 
For instance, in retinal pericytes under mild stress related to DR, autophagy may confer protection, 
while under more severe stress it could promote cell death [12]. Several observations seem to favor 
a cytoprotective role of autophagy in DR: in retinal pigment epithelial cells and in Müller cells the 
inhibition of autophagy increases HG-induced cell death [13, 15], while activation of autophagy 
protects cells from apoptosis [13]. In general, it is known that autophagy and apoptosis are under 
the control of common intracellular effectors, resulting in cross-regulation. Thus, autophagy would 
reduce the propensity of cells to undergo apoptosis, while apoptotic signaling, in turn, would inhibit 
autophagy [18, 19]. Although little is known of the balance between apoptosis and autophagy in 
retinal neurons during early phases of DR, a neuroprotective treatment may act by influencing this 
equilibrium. Indeed, there is clear evidence that neurons possess the machinery for autophagy, 
while an efficient autophagic function has been found to be positively associated with 
neuroprotection in different regions of the central nervous system [20-22], including the retina [6, 
23]. 
Apoptosis of retinal neurons can be effectively inhibited with the somatostatin neuropeptide 
analog octreotide (OCT) [24-29]. In particular, our data show that protecting retinal neurons from 
diabetic stress also reduces the expression and release of vascular endothelial growth factor 
(VEGF), suggesting that neuroprotective agents may decrease the risk, in the long term, of 
pathologic angiogenesis [24]. Different roles of endogenous neuropeptides, including somatostatin, 
in the regulation of autophagy have been recently highlighted [30], which may provide a better 
knowledge of the molecular mechanisms and the functional dynamics of the autophagic process as 
well as its pathophysiology. Therefore, we investigated a possible involvement of autophagy in the 
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neuroprotective effects exerted by OCT in our established ex vivo model of retinal explants cultured 
in HG [24]. 
 
2. Materials and Methods 
 
2.1. Animals 
The procedures were approved by the Ethics Committee in Animal Experiments of the 
University of Pisa (Pisa, Italy) and were in compliance with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research, the Italian guidelines for animal care (DL 116/92), 
and the EU Directive (2010/63/EU). All experimental procedures were performed to reduce both 
animal suffering and the number of animals used. C57BL/6J mice (Charles River Laboratories) 
were used in these studies. They were kept in a regulated environment (23 ± 1°C, 50 ± 5% 
humidity) with a 12-hour light/dark cycle (lights on at 8 AM) with food and water ad libitum. 
 
2.2. Ex-vivo retinal explants 
Retinas from 4- to 5-week-old mice of both sexes were dissected in Modified Eagle Medium 
(MEM; Sigma-Aldrich, St. Louis, MO, USA) and cut into 4 fragments. The fragments were 
transferred onto Millicell-CM culture inserts (Merck Millipore, Darmstadt, Germany) with ganglion 
cells up. The inserts were placed in 6-well tissue culture plates with 1 mL of serum-free culture 
medium composed of 50% MEM/HEPES (Sigma-Aldrich) containing 6 mM D-glucose, 25% 
Hank's buffer salt solution (Sigma-Aldrich), 25% PBS, 25 U/mL penicillin, 25 mg/mL 
streptomycin, 1 μg/mL amphotericin B, and 200 μM L-glutamine. The explants were incubated for 
10 days at 37°C under a humidified 95%/5% (vol/vol) mixture of air and CO2. The medium was 
changed every other day. The HG condition was realized by adding D-glucose to the culture 
medium to reach a concentration of 75 mM. As previously reported, although in different studies 
HG treatments have been performed using a wide variety of glucose concentrations, in our 
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experimental model treatments with 75 mM glucose are necessary to induce significant increases of 
apoptotic markers [24].  
Control experiments were performed using a culture medium containing 6 mM D-glucose 
and 69 mM mannitol. Consistent with our previous findings [24], the amount of apoptotic cell death 
in mannitol-treated explants, evaluated with western blot for cleaved caspase-3, was not 
significantly different from that in untreated explants (not shown). These observations were also in 
agreement with previous studies of rat retinal explants [31]. Based on these findings, untreated 
explants were used as controls. 
 
 
 
2.3. Pharmacologic treatments 
The somatostatin analogue octreotide (OCT, Sigma-Aldrich), a long-lasting agonist at the 
somatostatin subtype 2 (sst2) receptor [32-36], was used at 1 µM concentration according to our 
previous work [24]. Chloroquine (CQ, Sigma-Aldrich) is a lysosomotropic agent that prevents 
acidification of the lysosomal lumen and inhibits the activity of lysosomal enzymes [37]. It was 
used as an inhibitor of the autophagic flux at a concentration of 10 µM, according to the literature 
[38, 39].  
 
2.4. Western blot  
At the end of the incubation period, each retinal fragment was collected and lysed in 50 μL 
of 10 mM Tris/HCl, pH 7.6, containing 5 mM EDTA, 3 mM EGTA, 250 mM sucrose, and 1% 
SDS, and supplemented with a cocktail of protease and phosphatase inhibitors. Equal amounts of 
proteins were separated by 4-20% SDS-polyacrylamide gel electrophoresis and transferred onto 
nitrocellulose membrane using a Bio-Rad Trans-Blot Turbo System. The membranes were then 
probed using primary antibodies and directed to microtubule-associated protein light chain 3 (LC3) 
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(Cell Signaling Technology, Danvers, MA, USA, #4108), to p62 (Sigma-Aldrich, #P0068), to S6 
Ribosomal Protein phosphate (pS6) (Cell Signaling Technology, #2215), or to cleaved caspase-3 
(Cell Signaling Technology, #9664). After incubation with the appropriate horseradish-peroxidase-
conjugated secondary antibody, immunoreactive bands were visualized using the Clarity Western 
ECL substrate with a ChemiDoc XP imaging system (Bio-Rad Laboratories, Segrate, Milano, 
Italy). Bands were quantified for densitometry using the Image Lab software (Bio-Rad 
Laboratories) and normalized to GAPDH (Santa Cruz Biotechnology, Dallas, TX, USA, #sc-
25778).When appropriate, the primary antibody that recognises the protein independently of its 
phosphorylation state, i.e. S6 ribosomal protein (Cell Signaling Technology, #2317), was also used 
in reprobing experiments for normalization purposes. 
 
2.5. Immunofluorescence 
Retinal fragments were fixed in 4% paraformaldehyde in 0.1M phosphate buffer (PB) for 1 
h. They were stored overnight in 25% sucrose in PB and subsequently embedded in cryo-gel and 
frozen using liquid nitrogen. Sections (10 μm thick) were cut on a cryostat, mounted onto 
gelatinized slides and stored at -20°C until use. For immunostaining, sections were washed in PB 
and pre-incubated for 15 min at room temperature with 5% bovine serum albumin (BSA; Life 
Technologies) and 10% of normal goat serum (Life Technologies, Monza, Italy) in PB containing 
0.5% Triton X-100. The slides were then incubated overnight at 4°C with primary antibodies 
directed to LC3 (Sigma-Aldrich, #L8918; dilution 1:100), to p62 (Sigma-Aldrich, #P0067, dilution 
1:200) or to cleaved caspase-3 (Sigma-Aldrich, #C8487; dilution 1:400) diluted in PB containing 
0.5% Triton X-100. 
In double-label immunofluorescence experiments, the LC3 antibody was used in 
conjunction with antibodies directed to MAb115A10 (from Dr. S.C. Fujita, of the Mitsubishi Kasei 
Institute of Life Sciences, Tokyo, Japan; dilution 1:1000), gamma-aminobutyric acid transporter-1 
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(GAT-1, Merck Millipore, #AB1570; dilution 1:200), Disabled-1 (Dab1, Sigma Aldrich, 
#SAB4503448; dilution 1:300) , or ß tubulin III (Sigma Aldrich, #T8660; dilution 1:400). 
The double labeling experiments with LC3 antibodies in conjunction with antibodies 
directed to GAT-1 or to Dab1, which are all made in rabbit, were performed following published 
protocols [40]. Briefly, sections were first incubated with the primary antibody directed to LC3 for 
3 h at room temperature and then in anti-rabbit fluorescein-conjugated Fab fragment antibody 
(Jackson Immuno Research, Suffolk, UK, #JI111097003) for 1.5 h at room temperature. 
Subsequently, the slides were incubated in anti-rabbit unlabeled Fab fragment antibody (Jackson 
Immuno Research, # JI111007003) overnight at 4°C and then, after washes in PB, with the antibody 
directed to GAT-1 or to Dab1 for 3 h at room temperature. Following washes in PB, the sections 
were incubated with secondary anti-rabbit antibodies conjugated with Alexa-Fluor-546 (Life 
Technologies) at a dilution of 1:400 in PB containing 0.5% Triton X-100, for 1.5 h at room 
temperature. 
The slides were coverslipped with Fluoroshield Mounting Medium containing DAPI 
(Abcam, Cambridge, UK). Images were acquired using a Zeiss Axioskop 2 plus microscope 
equipped with the Axiocam MRC photocamera and the Axiovision software (Carl Zeiss, 
Oberkochen, Germany) or a Zeiss LSM 710 confocal microscope (Carl Zeiss). Final images were 
sized and optimized for contrast and brightness using Adobe Photoshop (Adobe Systems, Mountain 
View, CA, USA). The images of double-label immunofluorescence were checked for how they are 
perceived by the colorblind [41]. 
To perform quantitative analysis in LC3 immunostained retinas, at least five representative 
images acquired with the Zeiss Axioscop were selected for each retinal explant and four explants, 
each originating from a different retina, for experimental condition were analyzed. Each image was 
converted to grayscale and normalized to background using an image editing software (Adobe 
Photoshop). Mean gray levels were then measured in the area encompassing the ganglion cell layer 
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(GCL), the inner plexiform layer (IPL), the inner nuclear layer (INL), and the outer plexiform layer 
(OPL). 
 
2.6. Statistics 
Statistical significance of data between the groups was evaluated using unpaired Student’s t-
test (single comparisons) and one-way ANOVA (multiple comparisons) followed by the Tukey’s or 
Newman-Keuls post-tests. The results were expressed as means ± SEM. Prism 5 (GraphPad 
Software, Inc., La Jolla, CA, USA) was used to analyze the data. Differences with p < 0.05 were 
considered statistically significant. 
 
 
 
 
3. Results 
 
3.1 Autophagy in HG-treated explants and effects of OCT 
LC3 is an ubiquitin-like protein that may be found in an unconjugated, slow migrating form 
(LC3-I) or conjugated to the membranes of autophagic vesicles in a lipidated, fast migrating form 
(LC3-II) [42]. An increase in the expression of LC3-II reflects an increase of autophagosomes in the 
cells. As shown in figure 1A, HG reduced LC3-II levels to about one-half of those in control 
explants, while OCT treatment resulted in a dramatic increase of LC3-II indicating a remarkable 
accumulation of autophagic vesicles induced by the neuroprotectant. Since the lipidation of LC3 
may be the result of both induction and suppression of autolysosomal maturation, the measurement 
of p62, a cargo receptor for the autophagic degradation of ubiquitinated substrates that is degraded 
during autophagy [43], is a useful method to distinguish whether autophagosome accumulation is 
due to autophagy induction or rather to the inhibition of autophagy steps [42]. As shown in figure 
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1B, p62 levels were significantly increased in HG-treated explants, but they were not significantly 
different from control values in HG-treated explants incubated in the presence of OCT. Together, 
these data indicated that HG induced a decrease of autophagy, which was restored by the treatment 
with OCT. 
The regulation of autophagy involves a complex machinery, in which the main autophagy 
regulator is mammalian (or mechanistic) target of rapamycin (mTOR). An increase of mTOR 
activity inhibits, while a decrease of mTOR activity promotes, the autophagic flux [44]. To assess 
the involvement of mTOR in our experimental model, we evaluated the phosphorylation rate of 
protein S6. This protein  is phosphorylated as a consequence of mTOR activation [44], therefore the 
level of pS6 is commonly considered as a marker of mTOR activity [42]. Figure 1C shows that the 
ratio pS6/S6 was significantly increased in HG-treated explants, but it came back to control values 
in the presence of OCT, indicating that the changes in autophagic function observed in HG-treated 
explants with or without OCT are coupled to mTOR. 
 
3.2. Expression patterns of autophagic markers 
Changes in autophagic function could also be appreciated with immunohistochemistry. LC3 
immunofluorescence was detected in control, untreated explants (Fig. 2A), where LC3 
immunoreactivity was mainly localized to the OPL and to the GCL, with some sparse LC3 
immunostained puncta that could be also seen in the distal INL. Although in most explants the 
general picture was similar to that represented in figure 2A, in some cases only the OPL or the GCL 
immunolabeling could be observed. The LC3 immunostaining was mostly diffuse, with scattered 
aggregates (Fig. 2A, insets). In HG-treated explants, LC3 immunolabeling was dramatically 
reduced and only faint profiles could be observed in OPL and GCL (Fig. 2B), where 
immunostained puncta were barely visible (Fig. 2B, insets). When HG-treated explants were 
incubated in the presence of OCT, they displayed an intense LC3 immunostaining. The 
immunofluorescence in the OPL was relatively scarce and it was localized mainly to the INL and to 
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the GCL, with scattered immunofluorescent puncta also visible in the IPL (Fig. 2C). LC3 
immunostaining in the INL and GCL was characterized by strongly fluorescent aggregates (Fig. 2C, 
insets), which were particularly densely packed within the immunostained profiles in the GCL. The 
punctate appearance of LC3 immunolabeling was likely to be due to its presence in accumulating 
autophagosomes awaiting lysosomal degradation. A quantitative analysis of LC3 
immunofluorescence intensity observed in the different experimental conditions (Fig. 2D) 
confirmed a significant decrease of LC3 expression caused by HG and the increased values in the 
presence of OCT. 
 Consistent with the western blot data, the immunostaining patterns of p62 showed a marked 
increase of p62 in the presence of HG, which was reverted by OCT treatment. In particular, p62 
immunofluorescence was mostly localized to a few cells of the GCL in control explants (Fig. 3A) 
and in HG-treated explants in the presence of OCT (Fig. 3C). In contrast, explants incubated in HG 
alone displayed a widespread p62 immunofluorescence localized not only to the GCL, but also to 
the mid- and distal INL, where immunofluorescent profiles were characterized by strongly 
immunolabeled puncta (Fig. 3B). 
Double-label immunofluorescence was performed to gather some information about the 
cellular types expressing autophagy markers. To this aim, the antibody directed to LC3 was used in 
conjunction with other antibodies for the visualization of populations of bipolar cells, amacrine 
cells, and ganglion cells in explants treated with both HG and OCT. The MAb115A10 antibody 
recognizes an antigen expressed by rod and ON-type cone bipolar cells in the mouse retina [45]. As 
shown in figure 4A-C, the intensely immunolabeled LC3 puncta in the distal INL were not within 
MAb115A10 immunoreactive profiles, therefore ON-type bipolar cells did not appear to be the 
main site of autophagy regulation in the INL. However, a closer observation revealed that these 
bipolar cells contained a number of LC3 puncta showing dimmer immunostaining (Fig. 4C, inset), 
indicating that they may participate to autophagic mechanisms, although to a lesser extent. 
Regarding amacrine cells expressing LC3 immunoreactivity, double immunolabeling was 
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performed using an antibody directed to GAT-1, which identifies the majority of GABAergic 
amacrine cells [46]. Only a few LC3 immunostained cells also displayed GAT-1 immunoreactivity 
on their membrane (Fig. 4D-F), indicating that the most of LC3 expressing amacrine cells were not 
GABAergic. In particular, immunolabeled cell counting in  double labeled retinal sections indicated 
that the numbers of GAT-1 immunolabeled cells was similar to that of LC3 immunoreactive cells 
located in the proximal INL and that about 20% of them were double labeled. The presence of LC3 
immunoreactivity was also investigated in the glycinergic AII amacrine cells, identified with 
antibodies directed to Dab1 [47]. As shown in figure 4 G-I, many double-labeled profiles were 
observed in the proximal INL, indicating that the vast majority of LC3 immunostained cells were, 
in fact, glycinergic, AII amacrine cells. To evaluate the presence of LC3 puncta in ganglion cells, 
double label experiments were performed using an antibody directed to ß-tubulin III, which is 
expressed by ganglion cells [48]. As sown in figure 4J-L, virtually all LC3 immunostained profiles 
in the GCL were also ß-tubulin III immunolabeled, and vice-versa, indicating a central involvement 
of ganglion cells in autophagic modulation that may occur in DR. 
 
3.3. Effects of OCT on the autophagic flux in HG-treated retinas 
To investigate in more detail the effects of OCT on the autophagic machine, a set of 
experiments was conducted in the presence of CQ, an inhibitor of autophagy. In particular, CQ 
blocks lysosome acidification, thereby preventing its fusion with the autophagosome and inhibiting 
autophagosome degradation [49]. Thus, the extent of LC3 turnover in response to CQ reflects the 
rate of autophagic degradation, or autophagic flux [42]. To demonstrate that OCT was in fact 
enhancing the autophagic flux, we evaluated the LC3-II levels in the absence and in the presence of 
CQ. As shown in Fig. 5A, CQ treatment induced a significant increase of LC3-II levels in the 
explants treated with HG and an even greater increase in the explants treated with both HG and 
OCT. The analysis of the data by the LC3-II turnover assay [50] revealed that OCT significantly 
increased the LC3-II net flux in HG-treated retinal explants (Fig. 5B).  
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Consistent with these observations, in immunofluorescence experiments HG-treated explants 
incubated in the presence of CQ or of both OCT and CQ, displayed a LC3 immunofluorescence that 
was enhanced with respect to that in explants incubated with HG alone and that was extensively 
localized to the OPL, INL, IPL, and GCL (Fig. 6A-C). In the explants incubated in the presence of 
CQ, the LC3 immunoreactive profiles were characterized by large, brightly fluorescent puncta (Fig. 
6A-C, insets). A quantitative evaluation of the immunofluorescence intensity confirmed the data 
obtained with the western blots (Fig. 6D). In summary, the increases of LC3-II turnover, LC3-II net 
flux, and LC3-II aggregates in HG-treated retinas indicated that the CQ-induced blockade of the 
autophagic flux determined an accumulation of undegraded autophagosomes expressing LC3-II 
immunoreactivity and that OCT acts stimulating the autophagic flux. 
 
 
3.4. Effects of autophagy blockade on OCT antiapoptotic action 
To investigate the relationship between autophagy and apoptosis in HG-treated retinal 
explants and to evaluate the possible involvement of autophagy in the protective effects exerted by 
OCT, we evaluated the expression of cleaved (active) caspase-3 as a marker of apoptosis. As 
expected [24], apoptosis was increased in HG-treated explants and was reduced below control 
levels in explants treated with both HG and OCT (Fig. 7). Interestingly, in all the experimental 
conditions (untreated control, HG-treated, and HG-treated plus OCT), the administration of CQ 
provoked a marked increase of active caspase-3 levels. In particular, the protective effect of OCT in 
HG-treated explants was abolished by CQ. 
To better visualize the relationship between autophagy and apoptosis, LC3 and active caspase-3 
immunostainings were compared in retinal sections from of control, HG-treated, and HG plus OCT-
treated retinal explants. As shown in figure 10, in control explants basal LC3 immunoreactivity 
corresponded to the presence of scarce apoptotic profiles (Fig. 8A-C); in HG-treated explants, only 
faint LC3 immunostaining could be observed, and it was paralleled by an increase of active 
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caspase-3 immunostained cells (Fig. 8D-F); in HG-treated explants incubated in the presence of 
OCT, the appearance of strong LC3 immunoreactivity characterized by brightly immunofluorescent 
puncta corresponded to a pattern of active caspase-3 immunostaining that was similar to that 
observed in control explants (Fig. 8G-I). 
Together, these results indicated that the inhibition of autophagy caused cell death and, of interest, 
that OCT stimulation of the autophagic flux protected retinal neurons from HG-induced apoptosis. 
 
4. Discussion 
 
We have demonstrated recently that, in an ex vivo model of early DR, OCT is very effective 
in reducing both apoptosis and VEGF expression and release. In particular, our data indicated that 
VEGF levels directly depend on the efficacy of neuroprotection [24]. Therefore, both neural and 
vascular damages in DR may be prevented using neuroprotective substances in early phases of the 
disease [4] and the mechanisms mediating the neuroprotective properties of substances like OCT 
deserve attention. Here, we provide data supporting a central role of autophagy in such 
mechanisms. 
 
4.1. Autophagy and retinal disease 
Autophagic mechanisms are likely to be involved in the pathogenesis of different ocular 
diseases other than DR [9]. For example, a reduction of autophagosomes and autophagic flux has 
been reported both in retinas of mouse models of age-related macular degeneration (AMD) and in 
ocular tissues of AMD patients [51], suggesting that, in the presence of dysregulated autophagy, 
constant oxidative stress, increased protein aggregation, and inflammation may cause the 
pathological phenotype of AMD [52]. In addition, in a mouse model of retinitis pigmentosa, 
blockade of the autophagic flux has been found to be associated to photoreceptor degeneration [53]. 
Autophagy is also involved in glaucoma; although its effects in retinal ganglion cells and in their 
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axons are not always easy to resolve, autophagy is likely to mainly exert protective actions in this 
disease [54]. In general, our observations are consistent with these findings and with the view that 
autophagy plays a pro-survival role in the retina under noxious stimuli; however, there are also 
reports indicating that induction of autophagy may lead to the death of retinal neurons. Indeed, an 
increase of autophagic markers has been found to be associated to ganglion cell death induced by 
ischemia/reperfusion in rats [55] or to rod photoreceptor death in streptozotocin-treated, diabetic 
mice [56]. 
 
4.2. Autophagy and OCT-mediated neuroprotection in DR 
Our data demonstrate that, in ex vivo retinal explants, the stress induced by HG disrupts 
autophagy, leading to apoptotic cell death of retinal neurons, and that this decreased autophagy is 
associated with an up-regulation of mTOR activity. These observations are consistent with a 
nutrient regulation of mTOR induced by HG. Indeed, in nutrient-rich conditions, such as HG, 
mTOR is known to be activated and to promote synthetic activities and cell growth, while in 
nutrient-deficient conditions mTOR is inhibited and catabolic processes are activated to produce 
sufficient energy for survival [57]. This nutrient regulation of mTOR is likely to have an impact on 
the autophagic flux and on apoptotic levels in different circumstances. For instance, it has been 
reported that, in the mouse hippocampus, caloric restriction inhibits mTOR expression and function 
leading to increased autophagy, which results in neuroprotection [58, 59]. 
The multiple roles that peptides may play in the regulation of autophagy have been reviewed 
recently [30]. The somatostatin analog OCT is known to exert powerful neuroprotective actions in 
the retina [24-29, 60]. Our results show that the administration of this neuroprotectant to HG-treated 
retinal explants inhibits mTOR and re-activates the autophagy machine thus increasing the 
autophagic flux. This positive effect of OCT on autophagy is coupled to the OCT well-known anti-
apoptotic actions, since our results demonstrate that the anti-apoptotic efficacy of OCT is 
completely abolished when the autophagic flux is blocked by CQ. Interestingly, OCT has been 
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recently found to exert protective effects in the kidney after hepatic ischemia through induction of 
autophagy [61]. A wide variety of data support the notion that autophagy plays a fundamental role 
in preventing neurodegeneration [22, 62, 63], and perturbations of autophagy are thought to 
participate to the pathogenesis of all major neurodegenerative diseases [64, 65]. In our model of 
early DR, the neuroprotection afforded by OCT is mediated by the OCT-promoted activation of the 
autophagic flux. 
Interestingly, in the same experimental model of the present study we have observed recently 
that the neuroprotective effect OCT also results in inhibition of VEGF expression and release [24]. If the 
protective effect of OCT is mediated by mTOR inhibition and increased autophagy, the possibility 
exists that OCT may induce VEGF inhibition through the same pathway. In effect, it has been reported 
that blocking mTOR with rapamycin reduces VEGF expression in the retinas of streptozotocin-treated 
rats with DR [66] and VEGF release in cultured Müller cells in the presence of HG [13]. In addition, in 
retinal pigment epithelial cells, activation of mTOR has been found to be important for VEGF 
expression [67], while VEGF expression and/or release are reduced in the presence of mTOR 
inhibition obtained with rapamycin [68-70] or with other drugs [71-73]. 
Autophagy activation by OCT has been visualized within retinal layers using 
immunohistochemistry. In line with previous reports, LC3 immunoreactivity was localized to the 
OPL, INL, IPL, and GCL [56, 74]. In particular, LC3 immunoreactivity in HG-treated explants in 
the presence of OCT is significantly increased with respect to HG-treated explants without OCT, 
and it shows a pattern characterized by a number of cells in both the GCL and the INL containing 
many brightly immunofluorescent puncta. These observations, and in particular the appearance of 
the LC3 immunofluorescent puncta, indicate an increase of autophagosome formation induced by 
OCT. 
 
4.3. Retinal neuronal populations involved in the OCT-induced increase of autophagy 
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Our results show that, in HG-treated retinal explants, OCT induces an increase of LC3 
immunolabeled puncta in different neuronal types of the retina. In particular, ON-type bipolar cells 
(which include ON-cone bipolar cells and rod bipolar cells) appear to increase their LC3 expression 
in the presence of OCT, at least to a certain extent. However, the most intensely LC3 
immunolabeled profiles do not belong to these bipolar cells. Based on their localization in the mid- 
distal INL, they are likely to belong to other bipolar cells, which can be classified as OFF-type 
bipolar cells. In summary, in the presence of a stress caused by HG, the treatment with OCT 
induces an increase of LC3 puncta (indicating increased autophagy) in most, if not all, bipolar cells, 
especially the OFF-type. In addition to bipolar cells, virtually all ganglion cells also display bright 
LC3 puncta. Our previous studies showed that OCT is capable of protecting ex vivo mouse retinas 
from acute ischemic insults by inhibiting excessive glutamate release caused by ischemia [27, 28]. 
Since glutamate excitotoxicity is likely to play a role in the neuronal damage caused by HG [4], it is 
interesting to note that OCT-induced autophagy, mapped with LC3 immunofluorescence, is mainly 
localized to OFF bipolar and ganglion cells, which are known to be glutamatergic and to express 
ionotropic glutamate receptors [75]. 
A number of LC3 immunostained cells localize to the proximal INL, and therefore these 
cells are likely to be amacrine cells. We did not test the presence of LC3 in dopaminergic amacrine 
cells because these cells represent only a very sparse population in the retina. In addition, the classic 
localization pattern of cholinergic amacrine cells (two mirror-symmetric populations in the 
proximal INL and in the GCL) was not consistent with the observed localization of LC3 
immunostaining, and therefore double label experiments with LC3 together with a cholinergic 
marker were not performed. The number of LC3 immunostained amacrine cells results to be similar 
to that of GABAergic amacrine cells, indicating that a relatively high number of amacrine cells is 
involved in OCT-induced autophagic regulation. Regarding the type of amacrine cells that these 
cells may represent, our data show that only a small percentage of them are likely to be 
GABAergic. Since all amacrine cells in vertebrate retinas can be accounted for by the two 
Octreotide stimulates autophagy in high glucose-treated retinas 
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inhibitory neurotransmitters GABA and glycine [76], it follows that the majority of amacrine cells 
with OCT-induced LC3 immunoreactivity are glycinergic amacrine cells. In particular, the double 
label experiments with Dab1 indicate that these cells belong to the population of AII amacrine cells. 
In summary, an analysis of the neuronal populations in which, in the presence of a diabetic 
stress, OCT induces an increase of the autophagic flux suggests that autophagy may help 
glutamatergic neurons to re-equilibrate glutamate release and glutamate receptor-expressing 
neurons to resist to glutamate-driven excitation. 
 
5. Conclusion 
 
The data presented here indicate that a cross talk between apoptosis and autophagy is likely 
to exist in the retina. It may be altered by stressing conditions favoring apoptosis, but it may be re-
equilibrated by autophagy-stimulating substances. In particular, our results indicate that the reported 
antiapoptotic actions of OCT are the result of a stimulation of the autophagic flux. These 
observations support the possibility of targeting autophagic mechanisms for interventions in the 
early phases of DR. 
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Figure Legends 
 
Fig. 1. Representative western blotting images of LC3 (A), p62 (B) and phosphorylated S6 (pS6) 
(C) expression in control explants (UT), in HG-treated explants (HG), and in HG-treated explants in 
the presence of OCT (HG+OCT). GAPDH (A and B) and total S6 (C) were used as internal 
standards. Lower panels: densitometric analysis of LC3-II, p62 and pS6 levels relative to their 
respective standard. Results are expressed as fold change of UT (n = 6-13 explants, each originating 
from a different retina). *p < 0.05 relative to UT; §p < 0.001 relative to HG. 
 
Fig. 1. Representative confocal images showing the pattern of LC3 immunofluorescence (green) in 
control explants (A), in HG-treated explants (B), and in HG-treated explants in the presence of OCT 
(C). Insets are higher-power and higher-contrast images of the boxed areas of the corresponding 
color. Retinal layers are visualized with DAPI counterstain (blue). Scale bar, 20 µm (10 µm for the 
insets). D, quantitative analysis of immunofluorescence levels. Results are expressed as fold change 
of control (n = 4 explants, each originating from a different retina). *p < 0.001 relative to control; 
§p < 0.001 relative to HG. GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform 
layer; ONL, outer nuclear layer; OPL, outer plexiform layer. 
 
Fig. 2. Representative confocal images showing the pattern of p62 immunofluorescence (green) in 
control explants (A), in HG-treated explants (B), and in HG-treated explants in the presence of OCT 
(C). Insets are higher-power and higher-contrast images of the boxed areas. Retinal layers are 
visualized with DAPI counterstain (blue). Scale bar, 20 µm (10 µm for the insets). n = 4 explants, 
each originating from a different retina. Abbreviations as in figure 2. 
 
Fig. 4. Double-label immunofluorescence using antibodies directed to LC3 (A, D, G, and J) in 
conjunction with antibodies directed to MAb115A10 (B), GAT-1 (E), Dab1 (H) or ß-tubulin III (K). 
C, F, I, and L are overlay images. Panels A-C show that the brightly LC3 immunolabeled profiles 
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are distinct from MAb115A10 immunostained bipolar cells, although fainter LC3 immunolabeling 
can be seen within the somata of these cells (inset in C). Panels D-F show that only a few of the 
LC3 immunolabeled profiles are also GAT-1 immunostained (arrows). Panels G-I show that most 
LC3 immunolabeled cells in the proximal INL are also Dab1 immunostained (arrows), while 
several Dab1 immunoreactive somata result devoid of LC3 immunoreactivity (arrowheads). Finally, 
panels J-L show that virtually all LC3 immunolabeled profiles in the GCL are also ß-tubulin III 
immunostained, and vice-versa; the inset in L is a higher-power and higher-contrast image of the 
boxed area. Representative confocal images from n = 4 explants, each originating from a different 
retina. Scale bar, 20 µm in A-I, 37 µm in J-L, 10 µm in the insets. Abbreviations as in figure 2. 
 
Fig. 5. (A) Representative western blotting images of LC3 expression in HG-treated explants (HG), 
in HG-treated explants in the presence of CQ (HG+CQ), and in HG-treated explants in the presence 
of both CQ and OCT (HG+CQ+OCT). GAPDH was used as internal standard. Lower panel: 
densitometric analysis of LC3-II levels relative to GAPDH. Results are expressed as fold change of 
HG (n = 4-5 explants, each originating from a different retina). *p < 0.05 relative to HG; §p < 
0.0001 relative to HG, HG+CQ and HG+OCT. (B) LC3-II net flux determined by subtracting the 
densitometric value of LC3-II amount in HG samples non-treated with CQ from the corresponding 
sample treated with CQ, both in the absence and in the presence of OCT. Results are expressed as 
percentage of HG. *p < 0.05 relative to HG. 
 
Fig. 6. Representative confocal images showing the pattern of LC3 immunofluorescence (green) in 
HG-treated explants (A), in HG-treated explants in the presence of CQ (B), and in HG-treated 
explants in the presence of both CQ and OCT (C). Insets are higher-power and higher-contrast 
images of the boxed areas of the corresponding color. Retinal layers are visualized with DAPI 
counterstain (blue). Scale bar, 20 µm (10 µm for the insets). D, quantitative analysis of 
immunofluorescence levels. Results are expressed as fold change of HG (n = 4 explants, each 
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originating from a different retina). ; *p < 0.01, **p < 0.001 relative to HG; §p < 0.001 relative to 
HG+CQ. Abbreviations as in figure 2. 
 
Fig. 7. Representative western blotting images of cleaved (active) caspase-3 in: untreated control 
explants (UT), CQ-treated explants (CQ), HG-treated explants (HG), HG-treated explants incubated 
in the presence of OCT (HG+OCT) and HG-treated explants in the presence of both CQ and OCT 
(HG+CQ+OCT). GAPDH was used as internal standard. Lower panel: densitometric analysis of 
cleaved caspase-3 levels relative to GAPDH. Results are expressed as fold change of UT (n = 7-10 
explants, each originating from a different retina). *p < 0.05 relative to UT; §p < 0.05 relative to 
HG; #p < 0.0001 relative to HG+CQ and CQ; &p < 0.0001 relative to HG+OCT. 
 
Fig. 8. Retinal sections immunostained either with LC3 (A, D, and G) (green) or with cleaved 
(active) caspase-3 (B, E, and H) (red) antibodies. DAPI counterstain (C, F, and I) (blue) is shown to 
visualize the retinal layers. The sections were from untreated control explants (A-C), from HG-
treated explants (D-F), and from HG-treated explants incubated in the presence of OCT (G-I). 
Representative confocal images from n = 4 explants, each originating from a different retina. Scale 
bar, 20 µm. Abbreviations as in figure 2. 
 
 







